Compare PEB & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | LMAT |
|---|---|---|
| Founded | 2009 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2009 | 2006 |
| Metric | PEB | LMAT |
|---|---|---|
| Price | $18.02 | $79.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $13.30 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 1.7M | 232.8K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | 0.28% | ★ 0.93% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | N/A | ★ 1.42 |
| Revenue | ★ $1,475,544,000.00 | $249,602,000.00 |
| Revenue This Year | N/A | $14.21 |
| Revenue Next Year | $2.25 | $8.88 |
| P/E Ratio | ★ N/A | $56.39 |
| Revenue Growth | 1.53 | ★ 13.53 |
| 52 Week Low | $9.99 | $78.27 |
| 52 Week High | $19.93 | $118.01 |
| Indicator | PEB | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 40.19 |
| Support Level | $17.50 | $78.77 |
| Resistance Level | $19.73 | $83.71 |
| Average True Range (ATR) | 0.52 | 1.80 |
| MACD | 0.02 | 0.58 |
| Stochastic Oscillator | 61.09 | 37.45 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under the Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.